Regencell Corp (RGC): יחס מחיר להכנסות

Competing with the behemoths of classical neurology creates extreme survival risks for Regencell Bioscience (RGC). This historical P/S chart illustrates the dynamics of market expectations, where the level reflects the current multiple. The asset relies on a narrow niche of treating autism through Chinese medicine methods, which triggers skepticism among Western investors and establishes its reputation as a highly speculative instrument.

For Regencell Bioscience (RGC), whose revenues depend on innovative medical cycles rather than the broader economy, revenue serves as the primary valuation basis. The ratio of market capitalization to sales volume, illustrated through the company's rolling P/S, allows investors to filter out price noise and determine the fair value of the business relative to its operational scale, where low values signal potential for a price recovery.